Founded in 1997, Bay City Capital LLC is a life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. Nearly all the firm's partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members.

Since inception, Bay City Capital has managed eight life sciences venture capital funds representing $1.6 billion in capital. Five of these are general life sciences funds, and three are sector funds focused on specific areas of investment.

General Life Sciences Funds
Bay City Capital’s general life sciences funds represent approximately $1.3 billion in capital commitments. These funds target a diverse group of life sciences companies, across all stages of development.

Bay City Capital Fund V Formed in 2007 $500,000,000
Bay City Capital Fund IV Formed in 2004 $350,000,000
Bay City Capital Fund III Formed in 2001 $250,000,000
Bay City Capital Fund II Formed in 1999 $200,000,000
Bay City Capital Fund I Formed in 1997 $150,000,000

Sector Funds
Bay City Capital’s sector funds are unique venture capital funds targeting specific geographies or sectors within the life sciences. These funds were often formed in partnership with other firms.

Decheng Capital China Life Sciences USD Fund I Formed in 2011 $140,000,000
Birchmere Ventures III Formed in 2005 $47,000,000
North American Nutrition and Agribusiness Fund Formed in 1999 $111,000,000

Portfolio Companies
Bay City Capital funds have invested in a total of 100 portfolio companies covering a broad range of life science sectors, including biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, healthcare IT, nutrition, and agribusiness.

Some of these companies include: Calypso Medical, Hyperion Therapeutics (IPO in July 2012), Civitas Therapeutics, Dermira (IPO in October 2014), Sunesis Pharma(NASDAQ:SNSS) and Symyx Technologies (NASDAQ:SMMX).